Disc Medicine Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025. During the meeting, stockholders elected Georges Gemayel, Ph.D., Mark Chin, M.S., M.B.A., and Liam Ratcliffe, M.D., Ph.D. as Class II directors. Stockholders also approved, on a non-binding, advisory basis, the compensation paid to the company's named executive officers. It was recommended that future advisory votes on executive compensation be held annually. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.